Voices
Benjamin Walbaum
Photo from Benjamin Walbaum/X

Benjamin Walbaum: Efficacy of Anti-PD1 Therapy in PD1-High mRNA Tumors Across Multiple Cancer Types

Benjamin Walbaum, Medical Oncologist at Pontifical Catholic University of Chile, shared a post on X:

“New in ESMO Open, led by my friend Elia Seguí. The ACROPOLI trial tested PD1 mRNA as a tumor-agnostic biomarker for ICI.

ORR 17.9% PD1-high tumors, 33% with recent tissue.

Even in MSS CRC and pancreas PD-L1 IHC and proliferation. sig benefit Biomarkers matter.”

Title: Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial

Authors: E. Seguí, F. Brasó-Maristany, T. Pascual, E. Sanfeliu, I. Victoria, C. Saura, C. Hierro, A. López-González, Y. Izarzugaza, E. Ciruelos, J. Gavilá, F. Racca, J.M. Cejalvo, K. Amillano, L. Paz-Ares, M. Juan, E. Felip, E. Garralda, B. González, A. Arance, J. Martín-Liberal, B. Conte, B. Walbaum, A. Indacochea, O. Castillo, P. Blasco, F. Pardo, Á. Aguirre, V. Sirenko, X. González, P. Galván, A. Vivancos, J.M. Ferrero-Cafiero, A. Mulero-Sánchez, F. Salvador, G. Villacampa, R. Mesía, A. Cervantes, A. Prat, J. Tabernero

Read the Full Article in ESMO Open.

Benjamin Walbaum

More posts featuring Benjamin Walbaum on OncoDaily.

Á. Aguirre A. Arance A. Cervantes A. Indacochea A. López-González A. Mulero-Sánchez A. Prat A. Vivancos B. Conte B. González B. Walbaum Benjamin Walbaum C. Hierro C. Saura cancer E. Ciruelos E. Felip E. Garralda E. Sanfeliu E. Seguí Elia Seguí F. Brasó-Maristany F. Pardo F. Racca F. Salvador G. Villacampa I. Victoria J. Gavilá J. Martín-Liberal J. Tabernero J.M. Cejalvo J.M. Ferrero-Cafiero K. Amillano L. Paz-Ares M. Juan O. Castillo OncoDaily Oncology P. Blasco P. Galván R. Mesía T. Pascual V. Sirenko X. González Y. Izarzugaza